I’d also say that PAR will probably do better than the sector average ratios as it probably has a simpler business with lower overhead for its tighter focus on PPS rather than a multi drug portfolio, and supply and manufacturing outsourced to Bene.
PAR Price at posting:
$1.62 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)